Neurocrine Biosciences (NASDAQ:NBIX) CEO Kyle Gano Sells 300 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano sold 300 shares of the stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $141.97, for a total transaction of $42,591.00. Following the completion of the transaction, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at approximately $19,933,581.79. The trade was a 0.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $143.19 on Wednesday. The company has a market cap of $14.28 billion, a price-to-earnings ratio of 34.26, a PEG ratio of 0.94 and a beta of 0.21. The firm has a 50 day simple moving average of $141.14 and a 200 day simple moving average of $130.54. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $154.61.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Tuesday, October 28th. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.58 by $0.46. The business had revenue of $794.90 million during the quarter, compared to the consensus estimate of $746.61 million. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The firm’s revenue was up 27.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.81 EPS. As a group, analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Needham & Company LLC raised their price target on shares of Neurocrine Biosciences from $170.00 to $184.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Guggenheim lifted their target price on shares of Neurocrine Biosciences from $165.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Truist Financial reissued a “buy” rating and set a $172.00 target price (up previously from $165.00) on shares of Neurocrine Biosciences in a research note on Thursday, October 30th. Morgan Stanley lifted their target price on shares of Neurocrine Biosciences from $163.00 to $168.00 and gave the stock an “overweight” rating in a research note on Monday, October 20th. Finally, Wedbush reissued an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $170.26.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of large investors have recently bought and sold shares of the stock. Peak Retirement Planning Inc. grew its holdings in Neurocrine Biosciences by 23.7% in the third quarter. Peak Retirement Planning Inc. now owns 14,711 shares of the company’s stock worth $2,065,000 after purchasing an additional 2,818 shares during the period. Jones Financial Companies Lllp grew its holdings in Neurocrine Biosciences by 17.3% in the third quarter. Jones Financial Companies Lllp now owns 704 shares of the company’s stock worth $100,000 after purchasing an additional 104 shares during the period. State of Wyoming grew its holdings in Neurocrine Biosciences by 78.8% in the third quarter. State of Wyoming now owns 2,987 shares of the company’s stock worth $419,000 after purchasing an additional 1,316 shares during the period. Atle Fund Management AB grew its holdings in Neurocrine Biosciences by 16.1% in the third quarter. Atle Fund Management AB now owns 102,625 shares of the company’s stock worth $14,406,000 after purchasing an additional 14,233 shares during the period. Finally, Transcend Capital Advisors LLC acquired a new stake in Neurocrine Biosciences in the third quarter worth $312,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.